Department of Sport, Exercise and Rehabilitation, University of Northumbria at Newcastle, Newcastle upon Tyne, UK.
Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK.
Br J Sports Med. 2020 Mar;54(6):341-348. doi: 10.1136/bjsports-2017-098970. Epub 2018 Jun 22.
To examine the effects of short-term, medium-term and long-term resistance exercise training (RET) on measures of cardiometabolic health in adults.
Intervention systematic review.
MEDLINE and Cochrane Library databases were searched from inception to February 2018. The search strategy included the following keywords: resistance exercise, strength training and randomised controlled trial.
Randomised controlled trials published in English comparing RET≥2 weeks in duration with a non-exercising control or usual care group. Participants were non-athletic and aged ≥18 years.
A total of 173 trials were included. Medium-term and long-term RET reduced systolic blood pressure (-4.02 (95% CI -5.92 to -2.11) mm Hg, p<0.0001 and -5.08 (-10.04 to -0.13) mm Hg, p=0.04, respectively) and diastolic blood pressure (-1.73 (-2.88 to -0.57) mm Hg, p=0.003 and -4.93 (-8.58 to -1.28) mm Hg, p=0.008, respectively) versus control. Medium-term RET elicited reductions in fasted insulin and insulin resistance (-0.59 (-0.97 to -0.21) µU/mL, p=0.002 and -1.22 (-2.29 to -0.15) µU/mL, p=0.02, respectively). The effects were greater in those with elevated cardiometabolic risk or disease compared with younger healthy adults. The quality of evidence was low or very low for all outcomes. There was limited evidence of adverse events.
RET may be effective for inducing improvements in cardio metabolic health outcomes in healthy adults and those with an adverse cardio metabolic risk profile.
CRD42016037946.
研究短期、中期和长期抗阻运动训练(RET)对成年人心脏代谢健康指标的影响。
干预系统评价。
从建库至 2018 年 2 月,在 MEDLINE 和 Cochrane 图书馆数据库中进行检索。检索策略包括以下关键词:抗阻运动、力量训练和随机对照试验。
持续时间≥2 周的 RET 与不运动对照或常规护理组进行比较的随机对照试验,发表于英文文献中。参与者是非运动员且年龄≥18 岁。
共纳入 173 项试验。与对照组相比,中、长期 RET 可降低收缩压(-4.02(95% CI -5.92 至-2.11)mmHg,p<0.0001 和-5.08(-10.04 至-0.13)mmHg,p=0.04)和舒张压(-1.73(-2.88 至-0.57)mmHg,p=0.003 和-4.93(-8.58 至-1.28)mmHg,p=0.008)。中、长期 RET 可降低空腹胰岛素和胰岛素抵抗(-0.59(-0.97 至-0.21)µU/mL,p=0.002 和-1.22(-2.29 至-0.15)µU/mL,p=0.02)。与年轻健康成年人相比,具有较高心脏代谢风险或疾病的个体的效果更大。所有结局的证据质量均为低或极低。仅有有限的不良事件证据。
RET 可能对改善健康成年人和具有不良心脏代谢风险特征的成年人的心脏代谢健康结局有效。
PROSPERO 注册号:CRD42016037946。